{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'Reference', 'FDA Guidance for Industry (issued July 2009) \"Drug-induced liver injury: Premarketing', \"clinical evaluation'\", '//www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances', '/UCM174090.pdf', '89(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'Appendix 2:', 'ECOG Performance Status', 'GRADE', 'ECOG PERFORMANCE STATUS', '0', 'Fully active, able to carry on all pre-disease performance without', 'restriction', 'Restricted in physically strenuous activity but ambulatory and able to', '1', 'carry out work of a light or sedentary nature, e.g., light house work,', 'office work', '2', 'Ambulatory and capable of all selfcare but unable to carry out any work', 'activities; up and about more than 50% of waking hours', 'Capable of only limited selfcare; confined to bed or chair more than 50%', '3', 'of waking hours', '4', 'Completely disabled; cannot carry on any selfcare; totally confined to', 'bed or chair', '5', 'Dead', 'Reference', 'Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative', 'Oncology Group.Am J Clin Oncol. 1982;5:649-655.', '90(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'Appendix 3:', 'Highly Effective Methods of Contraception', 'Olaparib is regarded as a compound with medium/high foetal risk.', 'Male patients must use a condom during treatment and for 3 months after the last dose of', 'olaparib when having sexual intercourse with a pregnant woman or with a woman of', 'childbearing potential. Female partners of male patients should also use a highly effective', 'form of contraception if they are of childbearing potential (as listed below). Male patients', 'should not donate sperm throughout the period of taking olaparib and for 3 months following', 'the last dose of olaparib.', 'Acceptable Non-hormonal birth control methods include:', 'Total/True abstinence: When the patient refrains from any form of sexual intercourse and', 'this is in line with their usual and/or preferred lifestyle; this must continue for the total', 'duration of the trial and for at least 3 months after the last dose of study drug. [Periodic', 'abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods, or', 'declaration of abstinence solely for the duration of a trial) and withdrawal are not', 'acceptable methods of contraception]', 'Vasectomised sexual partner PLUS male condom. With participant assurance that partner', 'received post-vasectomy confirmation of azoospermia.', 'Tubal occlusion PLUS male condom', 'IUD PLUS male condom. Provided coils are copper-banded', 'Acceptable hormonal methods:', 'Normal and low dose combined oral pills PLUS male condom', 'Cerazette (desogestrel) PLUS male condom. Cerazette is currently the only highly', 'efficacious progesterone based pill.', 'Hormonal shot or injection (eg., Depo-Provera) PLUS male condom', 'Etonogestrel implants (e.g., Implanon, Norplant) PLUS male condom', 'Norelgestromin / EE transdermal system PLUS male condom', 'Intrauterine system [IUS] device (eg., levonorgestrel releasing IUS - -MirenaR) PLUS male', 'condom', 'Intravaginal device (e.g., EE and etonogestrel) PLUS male condom', '91(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}